Sep 22, 2020 / 12:00PM GMT
Operator
Good morning, my name is Lara, and I will be your conference operator today. At this time, I would like to welcome everyone to the Merck Oncology ESMO Virtual Investor Relations Event Conference Call. (Operator Instructions) Thank you.
I would now like to turn the call over to Peter Dannenbaum, Vice President, Investor Relations. Please go ahead.
Peter Dannenbaum - Merck & Co., Inc. - VP of IR
Thank you, Lara, and good morning. Welcome to Merck's 2020 ESMO Investor Call. Today, I'm joined by Dr. Roger Perlmutter, President of Merck Research Labs; Dr. Roy Baynes, Head of Global Clinical Development and Chief Medical Officer; Frank Clyburn, Chief Commercial Officer; and Mike Nally, Chief Marketing Officer.
Before we get started, I would like to remind you that some of the statements that we make during today's call may be considered forward-looking statements within the meaning of the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Such statements are made based on the current beliefs of Merck's management
Merck & Co Inc Oncology Virtual IR Briefing -- ESMO 2020 Transcript
Sep 22, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers